Skip to main content
All lobbying filings

FRESENIUS KABI USA LLC

Lobbying for FRESENIUS KABI USA LLC

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Expenses
$75,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Illinois

Official filing document

 Lobbyists on this filing 2
  • SARAH CHRISTINE D'ORSIE
    Previously held: Congressman Tom Davis
  • STEVEN CHASE WALKER New on this filing
    Previously held: Congressman Jodey Arrington

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 10
  • Centers For Medicare and Medicaid Services (CMS)
  • Commerce, Dept of (DOC)
  • Executive Office of the President (EOP)
  • Food & Drug Administration (FDA)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • Patent & Trademark Office (PTO)
  • SENATE
  • U.S. Trade Representative (USTR)
  • White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Lobbying activity 7
Pharmacy

PBM reform, including spread pricing, AWP setting and/or dispense rate policy, ASP policy, any willing pharmacy laws in Medicare, third party essential medicine testing

Trade (domestic/foreign)

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.

Medicare/Medicaid

PBM reform, patent reform, ASP reform, international reference pricing, IRA Medicare negotiation, inflation penalty, most favored nations executive order, AWP reform, U.S. manufacturer preferencing, Medicare conditions of participation relating to resiliency standards linked to government reimbursement, 340b reform including PBM-owned 340b pharmacies, Medicare formulary policy and specialty tier reform, generics on generic tiers, Medicaid generics penalty, IRA inflationary penalty, manufacturer discount program

Taxation/Internal Revenue Code

BEAT, AMT, U.S. manufacturing incentives

Health Issues

Drug pricing, PBM Reform, patent reform, biosimilars, generics, medical devices, FDA approvals, DEHP

Manufacturing

Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers

Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem